广州维力医疗器械股份有限公司 控股股东、实际控制人行为规范 广州维力医疗器械股份有限公司 控股股东、实际控制人行为规范 （2025 年 8 月修订） 第一章 总则 第一条 为引导和规范广州维力医疗器械股份有限公司（以下简称"公司" 或"本公司"）控股股东、实际控制人的行为，切实保护公司和其他股东的合法 权益，根据《公司法》《证券法》《上海证券交易所股票上市规则》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作》等相关规定，特制定本行为 规范。 第二条 公司的控股股东、实际控制人适用本行为规范。 第三条 公司控股股东、实际控制人应当依照法律、行政法规、中国证监会 和证券交易所的规定行使权利、履行义务，维护上市公司利益。 第四条 公司控股股东、实际控制人应当遵守下列规定： （一）依法行使股东权利，不滥用控制权或者利用关联关系损害公司或者其 他股东的合法权益； （二）严格履行所作出的公开声明和各项承诺，不得擅自变更或者豁免； （三）严格按照有关规定履行信息披露义务，积极主动配合公司做好信息披 露工作，及时告知公司已发生或者拟发生的重大事件； （四）不得以任何方式占用公司资金； （五）不得强令、指使或者要 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-053 广州维力医疗器械股份有限公司 关于拟回购注销公司部分限制性股票减少注册资本 暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 根据《中华人民共和国公司法》等相关法律、法规的规定，公司拟减少注册资 本的，公司债权人自接到公司通知起 30 日内、未接到通知者自本公告披露之日起 45 日内，均有权凭有效债权文件及相关凭证要求公司清偿债务或者提供相应担保， 逾期未提出权利要求申报债权的，不会因此影响其债权的有效性，相关债务（义务） 将由公司根据原债权文件的约定继续履行。 （一）债权申报所需材料 公司各债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和 国公司法》等相关法律法规的规定向公司提出书面请求，并随附有关证明文件。债 权人申报所需材料包括：公司债权人可持证明债权债务关系存在的合同、协议及其 他凭证的原件及复印件到公司申报债权。债权人为法人的，需同时携带法人营业执 照副本原件及复印件、法定代表人身份证明文件； ...

2025 年第一次临时股东大会的 北京市中伦（深圳）律师事务所 关于广州维力医疗器械股份有限公司 二〇二五年八月 法律意见书 北京市中伦（深圳）律师事务所 关于广州维力医疗器械股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：广州维力医疗器械股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、中国证监会发布的《上 市公司股东会规则》（下称"《股东会规则》"）及公司现行章程（下称"《公司章 程》"）的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受广州 维力医疗器械股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年 第一次临时股东大会（下称"本次股东大会"），并就本次股东大会的召集和召开 程序、召集人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表 法律意见。 一、本次股东大会的召集和召开程序 为召开本次股东大会，公司董事会已于 2025 年 7 月 31 日在《公司章程》规 定的信息披露媒体上公告了会议通知。该通知载明了会议的召开方式、召开时间 和召开地点，对会议议题的内容进行了充分披露，说明了股东有权出席并可委托 代理人出席和行使表决权，明确了 ...

(一)股东大会召开的时间：2025 年 08 月 15 日 (二)股东大会召开的地点：广州市番禺区化龙镇国贸大道南 47 号公司一号楼二 楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 169 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 161,223,461 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 55.0498 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长向彬先生主持，大会采用现场投票 和网络投票相结合的表决方式进行表决，会议的召开和表决方式符《公司法》和 证券代码：603309 证券简称：维力医疗 公告编号：2025-052 广州维力医疗器械股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 ...

格隆汇8月15日丨维力医疗(603309.SH)在互动平台表示，公司暂时没有布局脑科介入导管领域，但公司 有颅脑引流管等输入神经外科器械类相关产品布局，同时公司将积极关注行业发展趋势，结合公司发展 战略，择机布局脑科其他类医疗器械新领域。 ...

Group 1 - The core viewpoint of the articles highlights the recent movements of social security funds in the stock market, with 16 new stocks being added to their portfolio in the second quarter [1] - A total of 384 companies have disclosed their semi-annual reports, revealing the actions of institutional investors through the top ten circulating shareholders [1] - Social security funds appeared in 57 stocks, with 16 new positions, 15 increased holdings, 15 reduced holdings, and 11 stocks where the holding amount remained unchanged [1] Group 2 - Among the newly established stocks, the highest number of social security fund appearances in the top ten circulating shareholders is in Su Shi Testing, with three funds holding a total of 14.86 million shares, accounting for 2.94% of circulating shares [1] - The stock with the highest holding ratio among the new positions is Zhong Chumei, with a holding ratio of 3.45%, followed by Beiding Co., Ltd. at 3.16% [1] - The stock with the largest holding amount among the new positions is Satellite Chemical, with 20.17 million shares held, followed by Su Shi Testing and Zhongyuan Expressway with 14.86 million shares and 13 million shares, respectively [1] Group 3 - In terms of performance, 15 of the newly established stocks reported year-on-year net profit growth, with the highest increase being 496.60% for Xin Qiang Lian, which achieved a net profit of 399.61 million yuan [2] - Other companies with significant net profit growth include Ta Pai Group and Guo Mai Culture, with increases of 92.47% and 80.38%, respectively [2] - A detailed list of newly established stocks by social security funds includes various companies across different industries, such as Zhong Chumei in basic chemicals and Beiding Co., Ltd. in home appliances [2]

Group 1 - The stock price of Weili Medical is reported at 14.78 yuan, down by 0.16 yuan from the previous trading day, with an intraday high of 15.04 yuan and a low of 14.72 yuan, and a trading volume of 89,168 lots, amounting to 1.32 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, covering various fields such as anesthesia, respiratory, and urology, with main products including tracheal intubation, laryngeal masks, and urinary catheters [1] - A temporary shareholders' meeting is scheduled for August 15 to review 15 proposals, including the repurchase and cancellation of restricted stock, changes to registered capital, and amendments to the company's articles of association, which will be held at the company's headquarters in Panyu District, Guangzhou, with participation options available both on-site and online [1]

Core Viewpoint - The company, Weili Medical, is currently facing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Weili Medical's stock closed at 14.78 yuan, down 1.07%, with a rolling PE ratio of 18.47 times and a total market capitalization of 4.329 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, and sales of medical catheters in areas such as anesthesia, urology, respiration, and hemodialysis [1]. - The latest financial report for the first half of 2025 shows the company achieved a revenue of 745 million yuan, a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17%, with a gross profit margin of 45.04% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Weili Medical at the 41st rank within the industry [1][2]. - The industry shows a wide range of PE ratios, with the highest being 20.62 times for Antu Biology and the lowest at 11.18 times for Jiuan Medical [2].

Group 1 - The company has signed a partnership agreement to establish a medical industry investment partnership named "Weizhi Medical Navigation (Suzhou) Medical Industry Investment Partnership (Limited Partnership)" with several investment entities, aiming to leverage professional investment resources for strategic development [2] - The company plans to contribute RMB 37.5 million, accounting for 25% of the total committed capital of RMB 150 million for the partnership [2] - The partnership has completed its business registration procedures as of June 24, 2025 [3] Group 2 - The partnership has successfully completed the private investment fund registration with the Asset Management Association of China, obtaining the private fund registration certificate on August 7, 2025 [4] - The fund is managed by Xianglv Venture Capital Management (Guangzhou) Co., Ltd., and the registration code is SBCS25 [4] - The company will closely monitor the operation of the investment fund and fulfill its information disclosure obligations as required by relevant laws and regulations [4]

Core Viewpoint - Guangzhou Weili Medical Instrument Co., Ltd. is actively participating in the establishment of an industrial investment fund to leverage professional investment management advantages and resources, aiming to support its strategic development plan [2][4]. Group 1: Investment Details - The company signed a partnership agreement on June 23, 2025, to become a limited partner in the "Weizhi Medical Navigation (Suzhou) Medical Industry Investment Partnership" with a total fundraising target of RMB 150 million, contributing RMB 37.5 million, which is 25% of the total [2]. - The fund's establishment has been completed with the necessary business registration procedures [3]. Group 2: Recent Progress - The fund has completed the private investment fund registration with the Asset Management Association of China, obtaining the private fund registration certificate on August 7, 2025 [4]. - The fund is managed by Oak Ridge Venture Capital Management (Guangzhou) Co., Ltd., and the registration code is SBCS25 [4].